Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cyclophosphamide + carboplatin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel + cyclophosphamide + carboplatin is a combination chemotherapy regimen composed of three cytotoxic agents commonly used in the treatment of various cancers, particularly gynecologic and breast malignancies. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division by promoting tubulin polymerization and preventing microtubule disassembly. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to apoptosis in rapidly dividing cells. Carboplatin is a platinum-based compound that forms DNA adducts, resulting in inhibition of DNA synthesis and function. This combination exploits different mechanisms to maximize antitumor efficacy by targeting cancer cells at multiple points in the cell cycle.
- Brand names
- TaxolParaplatinCytoxan
- Other names
- Paclitaxel/Carboplatin/Cyclophosphamide combinationSLU breast cancer regimen
02
Targets
DNA
Beyond the preview
Go deeper on paclitaxel + cyclophosphamide + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cyclophosphamide + carboplatin.